Comparison of complications and shocks in paediatric and young transvenous and subcutaneous implantable cardioverter-defibrillator patients

被引:17
|
作者
Quast, A. B. E. [1 ]
Brouwer, T. F. [1 ]
Kooiman, K. M. [1 ]
van Dessel, P. F. H. M. [1 ]
Blom, N. A. [2 ]
Wilde, A. A. M. [1 ]
Knops, R. E. [1 ]
机构
[1] Univ Amsterdam, Amsterdam Cardiovasc Sci, Dept Clin & Expt Cardiol, Amsterdam UMC,Heart Ctr, Amsterdam, Netherlands
[2] Univ Amsterdam, Dept Paediat Cardiol, Amsterdam UMC, Amsterdam, Netherlands
关键词
Implantable cardioverter-defibrillator; Device-related complications; Inappropriate therapy; Paediatric; Young; Subcutaneous ICD; CLINICAL-EXPERIENCE; CHILDREN; ADULTS;
D O I
10.1007/s12471-018-1186-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundYoung implantable cardioverter-defibrillator (ICD) patients are prone to complications and inappropriate shocks (IAS). The subcutaneous ICD (S-ICD) may avoid lead-related complications. This study aims to describe the incidence and nature of device-related complications in young transvenous ICD (TV-ICD) and S-ICD patients.MethodsSingle-chamber TV-ICD and S-ICD patients up to and including the age of 25years implanted between 2002 and 2015 were retrospectively analysed. Complications were defined as device-related complications requiring surgical intervention. IAS were defined as shocks for anything other than ventricular tachycardia or ventricular fibrillation. Follow-up data were collected 5years post-implantation. Kaplan-Meier estimates for complications at 5-year follow-up were calculated with acorresponding 95% confidence interval.ResultsEighty-one patients (46TV-ICD, 35S-ICD) were included (median age 19.0 (IQR 16.0-23.0) and 16.5 (IQR 13.0-20.2) years respectively). Median follow-up was 60 and 40months respectively. All-cause complication rate was 34% in the TV-ICD group and 25% in the S-ICD group (p=0.64). TV-ICD patients had more lead complications: 23% (10-36%) versus 0% (p=0.02). The rate of infections did not differ between TV-ICD and S-ICD: 2% (0-6%) versus 10% (0-21%) (p=0.15). No systemic infections occurred in the S-ICD patients. The rates of IAS were similar, TV-ICD 22% (9-35%) versus S-ICD 14% (0-30%) (p=0.40), as were those for appropriate shocks: 25% (11-39%) versus 27% (6-48%) (p=0.92).ConclusionThe rates of all-cause complications in this cohort were equal, though the nature of the complications differed. S-ICD patients did not suffer lead failures or systemic infections. An era effect is present between the two groups.
引用
收藏
页码:612 / 619
页数:8
相关论文
共 50 条
  • [31] Evaluation of subcutaneous implantable cardioverter-defibrillator performance in patients with ion channelopathies from the EFFORTLESS cohort and comparison with a meta-analysis of transvenous ICD outcomes
    Lambiase, Pier D.
    Eckardt, Lars
    Theuns, Dominic A.
    Betts, Timothy R.
    Kyriacou, Andreas L.
    Duffy, Elizabeth
    Knops, Reinoud
    HEART RHYTHM O2, 2020, 1 (05): : 326 - 335
  • [32] Eligibility of patients with temporary paced rhythm for a subcutaneous implantable cardioverter-defibrillator
    Opielowska-Nowak, Barbara
    Kempa, Maciej
    Budrejko, Szymon
    Slawinski, Grzegorz
    Raczak, Grzegorz
    KARDIOLOGIA POLSKA, 2022, 80 (12) : 1232 - 1237
  • [33] Quantification of Electromechanical Coupling to Prevent Inappropriate Implantable Cardioverter-Defibrillator Shocks
    Keene, Daniel
    Shun-Shin, Matthew J.
    Arnold, Ahran D.
    Howard, James P.
    Lefroy, David
    Davies, D. Wyn
    Lim, Phang Boon
    Ng, Fu Siong
    Koa-Wing, Michael
    Qureshi, Norman A.
    Linton, Nick W. F.
    Shah, Jaymin S.
    Peters, Nicholas S.
    Kanagaratnam, Prapa
    Francis, Darrel P.
    Whinnett, Zachary, I
    JACC-CLINICAL ELECTROPHYSIOLOGY, 2019, 5 (06) : 705 - 715
  • [34] Transvenous extraction of implantable cardioverter-defibrillator leads under advisory-A comparison of Riata, Sprint Fidelis, and non-recalled implantable cardioverter-defibrillator leads
    Brunner, Michael P.
    Cronin, Edmond M.
    Jacob, Jessen
    Duarte, Valeria E.
    Tarakji, Khaldoun G.
    Martin, David O.
    Callahan, Thomas
    Borek, P. Peter
    Cantillon, Daniel J.
    Niebauer, Mark J.
    Saliba, Walid I.
    Kanj, Mohamed
    Wazni, Oussama
    Baranowski, Bryan
    Wilkoff, Bruce L.
    HEART RHYTHM, 2013, 10 (10) : 1444 - 1450
  • [35] The implantable cardioverter-defibrillator
    Greene, HL
    CLINICAL CARDIOLOGY, 2000, 23 (05) : 315 - 326
  • [36] The subcutaneous implantable cardioverterdefibrillator should be considered for all patients with an implantable cardioverter-defibrillator indication
    Tan, Jian Liang
    Russo, Andrea M.
    HEART RHYTHM O2, 2022, 3 (05): : 589 - 596
  • [37] Predictors and Clinical Impact of Inappropriate Implantable Cardioverter-Defibrillator Shocks in Korean Patients
    Yang, Jeong Hoon
    Byeon, Kyeongmin
    Yim, Hye Ran
    Park, Jung Wae
    Park, Seung-Jung
    Huh, June
    Kim, June Soo
    On, Young Keun
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2012, 27 (06) : 619 - 624
  • [38] Implantable Cardioverter-Defibrillator Shocks Epidemiology, Outcomes, and Therapeutic Approaches
    Borne, Ryan T.
    Varosy, Paul D.
    Masoudi, Frederick A.
    JAMA INTERNAL MEDICINE, 2013, 173 (10) : 859 - 865
  • [39] Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: A systematic review and meta-analysis of inappropriate shocks and complications
    Nordkamp, Louise R. A. Olde
    Postema, Pieter G.
    Knops, Reinoud E.
    van Dijk, Nynke
    Limpens, Jacqueline
    Wilde, Arthur A. M.
    de Groot, Joris R.
    HEART RHYTHM, 2016, 13 (02) : 443 - 454
  • [40] Inappropriate implantable cardioverter-defibrillator shocks in repaired tetralogy of fallot patients: Prevalence and electrophysiological mechanisms
    Goldenthal, Isaac L.
    Rosenbaum, Marlon S.
    Lewis, Matthew
    Sciacca, Robert R.
    Garan, Hasan
    Biviano, Angelo B.
    IJC HEART & VASCULATURE, 2020, 28